| 9.86 -0.29 (-2.86%) | 03-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.32 | 1-year : | 14.39 |
| Resists | First : | 10.55 | Second : | 12.32 |
| Pivot price | 10.06 |
|||
| Supports | First : | 9.31 | Second : | 8.55 |
| MAs | MA(5) : | 10 |
MA(20) : | 10.05  |
| MA(100) : | 10.01 |
MA(250) : | 7.42 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 60.6 |
D(3) : | 58.4 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 12.4 | Low : | 3.29 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMTX ] has closed above bottom band by 20.0%. Bollinger Bands are 62% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.09 - 10.15 | 10.15 - 10.21 |
| Low: | 9.58 - 9.64 | 9.64 - 9.71 |
| Close: | 9.74 - 9.85 | 9.85 - 9.97 |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Fri, 06 Mar 2026
Immatics (NASDAQ:IMTX) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Thu, 05 Mar 2026
Immatics NV earnings beat by €0.13, revenue topped estimates - Investing.com
Thu, 05 Mar 2026
Immatics (IMTX) Projects Promising Developments for 2026 After R - GuruFocus
Thu, 05 Mar 2026
Immatics: Q4 Earnings Snapshot - marketscreener.com
Thu, 05 Mar 2026
Immatics: Q4 Earnings Snapshot - WKYC
Thu, 05 Mar 2026
Immatics Earnings Report: Q4 Overview - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 5.993e+007 (%) |
| Held by Institutions | 18.8 (%) |
| Shares Short | 5,460 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3342e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -141.6 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 53.2 % |
| Return on Equity (ttm) | -16.3 % |
| Qtrly Rev. Growth | 8.476e+007 % |
| Gross Profit (p.s.) | -65.96 |
| Sales Per Share | -22.09 |
| EBITDA (p.s.) | -6.71176e+007 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -176 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.45 |
| Price to Cash Flow | 3.32 |
| Dividend | 0 |
| Forward Dividend | 5.56e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|